136833-36-8

Basic information

• Product Name: 5-CHLORO-2,4-DINITROBENZOIC ACID
• Synonyms: 5-CHLORO-2,4-DINITROBENZOIC ACID;3-Chloro-4,6-dinitrobenzoicacid
• CAS NO: 136833-36-8
• Molecular Formula: C₇H₃ClN₂O₆
• Molecular Weight: 246.56
• EINECS: 200-258-5
• Mol File: 136833-36-8.mol
• Article Data: 11

Chemical Properties

• Melting Point: 180-182°C
• Boiling Point: 429.8°C at 760 mmHg
• Flash Point: 213.7°C
• Appearance: /
• Density: 1.791g/cm³
• Vapor Pressure: 3.76E-08mmHg at 25°C
• Refractive Index: 1.666
• CAS DataBase Reference: 5-CHLORO-2,4-DINITROBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CHLORO-2,4-DINITROBENZOIC ACID(136833-36-8)
• EPA Substance Registry System: 5-CHLORO-2,4-DINITROBENZOIC ACID(136833-36-8)

Safety Data

• Statements: 20/21/22-36/37/38-42/43
• Safety Statements: 28-36/37/39-45
• Hazardous Substances Data: 136833-36-8(Hazardous Substances Data)

Usage

General Description

The chemical 5-CHLORO-2,4-DINITROBENZOIC ACID, also known as CDNB, is a yellow crystalline solid that is commonly used as a substrate for the assay of glutathione S-transferase activity. It is a derivative of benzoic acid and contains a chlorine atom and two nitro groups on the benzene ring. CDNB is often used in biochemical and pharmacological research to study the enzyme glutathione S-transferase, which plays a crucial role in detoxification and drug metabolism. It is also employed in the development of various pharmaceuticals and agrochemicals due to its reactivity and ability to form conjugates with glutathione. Additionally, CDNB has been investigated for its potential as an anticancer agent and as a tool for studying drug resistance in cancer cells.

InChI:InChI=1/C7H3ClN2O6/c8-4-1-3(7(11)12)5(9(13)14)2-6(4)10(15)16/h1-2H,(H,11,12)

Upstream product

• 535-80-8 3-chlorobenzoate 
• 51676-74-5 1-chloro-5-methyl-2,4-dinitrobenzene 

Downstream Products

• 855200-25-8 2,4-dinitro-5-(N'-phenyl-hydrazino)-benzoic acid 

Relevant articles and documents

Quinazolinone compounds antagonizing NODDDD1/2 receptor signaling pathway

I II Of the compounds are capable of being used for immunotherapy of organisms by antagonizing NODDDD1/2 signaling pathway activation, and in particular can be used for treating tumors, and belongs to the technical field of medicines and.

Discovery of 1,4-Benzodiazepine-2,5-dione (BZD) Derivatives as Dual Nucleotide Binding Oligomerization Domain Containing 1/2 (NOD1/NOD2) Antagonists Sensitizing Paclitaxel (PTX) to Suppress Lewis Lung Carcinoma (LLC) Growth in Vivo

Nucleotide-binding oligomerization domain-like receptors (NLRs) are intracellular sensors of pathogen-Associated molecular patterns (PAMPs) and damage-Associated molecular patterns (DAMPs). Previously, we reported nucleotide-binding oligomerization domain-containing protein 1 (NOD1) antagonists (11, 12) and a NOD2 antagonist (9) that sensitized docetaxel (DTX) or paclitaxel (PTX) treatment for breast or lung cancer. In this article, we describe for the first time a 1,4-benzodiazepine-2,5-dione (BZD) derivative (26bh) that acts as a dual NOD1/NOD2 antagonist and inhibits both nuclear factor B (NF-B) and mitogen-Activated protein kinase (MAPK) inflammatory signaling, thereby sensitizing PTX to suppress Lewis lung carcinoma (LLC) growth. After investigation of the compound's cytotoxicity, a systematic structure-Activity relationship (SAR) was completed and revealed several key factors that were necessary to maintain antagonistic ability. This study establishes the possibility for using adjuvant treatment to combat cancer by antagonizing both NOD1 and NOD2 signaling.

Compound and application thereof

The invention discloses a compound and application thereof. The compound is the compound shown in the formula (I) or a stereoisomer or a pharmaceutical acceptable salt or solvate or a prodrug of the compound shown in the formula (I). The compound can restrain tumor cell proliferation through the effect RRM2, and restrain tumor stem cell regeneration, thereby being effectively used for preparing medicine for preventing or treating proliferative diseases and particularly anti-cancer medicine.